ArticleJournal of clinical medicine2022
Statins and Colorectal Cancer Risk: A Population-Based Case-Control Study and Synthesis of the Epidemiological Evidence.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Association between statin use and the risk of colorectal cancer in patients with inflammatory bowel disease: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis.Current medicinal chemistry · 2024Pooled it
- Dose-response effect of statins on colorectal cancer risk in IBD: a nationwide cohort study.BMC cancer · 2026Observational
- Trends in ischemic heart disease mortality among older adults with co-existing colorectal cancer in the US (1999-2023): a 25-Year retrospective study.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Article
- Obesity-Related Cancers in Relation to Use of Statins and Testosterone Replacement Therapy Among Older Women: SEER-Medicare 2007-2015.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Pharmacologic Potential of Statins in Cancer Prevention: Colo-Rectal Cancer Risk in Dyslipidemic Patients from a Korean Nationwide Cohort.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Sex Differences in Colorectal Cancer: Epidemiology, Risk Factors, and Clinical Outcomes.Journal of clinical medicine · 2025Review
- Proton pump inhibitors and all-cause mortality in colorectal cancer.Scientific reports · 2025Article
- Targeting PAR-2-driven inflammatory pathways in colorectal cancer: mechanistic insights from atorvastatin and rosuvastatin treatment in cell line models.Translational cancer research · 2025Article
- Statins and long-term risk of revision surgery after total hip arthroplasty in osteoarthritis: a multi-source data linkage study.Frontiers in pharmacology · 2025Article
- Pravastatin prevents colitis-associated carcinogenesis by reducing CX3CR1Scientific reports · 2024Article
- The role of gut microbiota and drug interactions in the development of colorectal cancer.Frontiers in pharmacology · 2023Review
- XGBoost algorithm and logistic regression to predict the postoperative 5-year outcome in patients with glioma.Annals of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
(1) Background: The pleiotropic effects of statins may explain a chemoprotective action against colorectal cancer (CRC). Many studies have tested this hypothesis, but results have been inconsistent so far. Moreover, few have examined statins individually which is important for determining whether there is a class effect and if lipophilicity and intensity may play a role. (2) Methods: From 2001-2014, we carried out a study comprised of 15,491 incident CRC cases and 60,000 matched controls extracted from the primary healthcare database BIFAP. We fit a logistic regression model to compute the adjusted-odds ratios (AOR) with their 95% confidence intervals (CIs). Additionally, we carried out a systematic review and meta-analysis. (3) Results: Current use of statins showed a reduced risk of CRC (AOR = 0.87; 95% CI: 0.83-0.91) not sustained after discontinuation. The association was time-dependent, starting early (AOR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.